Bibliographic Details
| Title: |
Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy. |
| Authors: |
Joudaki, Shamim, Oladipupo, Olamide, Carbery, Isabel, Lenti, Marco Vincenzo, Selinger, Christian P. |
| Source: |
Alimentary Pharmacology & Therapeutics; May2025, Vol. 61 Issue 9, p1430-1436, 7p |
| Subject Terms: |
PREGNANT women, INFLAMMATORY bowel diseases, RANDOM effects model, ODDS ratio, ELECTRONIC information resource searching |
| Abstract: |
Background: Inflammatory Bowel Disease (IBD) requires maintenance of remission during pregnancy to avoid poor maternal and fetal outcomes. Intrahepatic cholestasis of pregnancy (ICP) could also increase these risks. Aims: To examine the prevalence of ICP in pregnancies with IBD and associations with thiopurine exposure. Methods: An electronic search of MEDLINE, EMBASE, and EMBASE Classic databases using search terms for IBD and ICP from inception to 10th September 2024 was performed. Studies involving pregnant adults with a confirmed diagnosis of IBD reporting ICP were included. Prevalence and event numbers for ICP were pooled using a random effects model. Results: We identified two case reports, a case series of eight cases, and three cohort studies. Pooled prevalence of ICP in 1603 pregnancies with IBD was 3% (95% confidence interval [CI] 1.0%–7.0%). One cohort study reported that the prevalence of ICP in IBD was significantly higher compared to the general population (odds ratio [OR] 3.08 [95% CI 1.11–8.56], p = 0.039). Meta‐analysis showed that thiopurine exposure was associated with an increased risk of ICP, OR 6.65 [95% CI 3.10–14.25]. One cohort study showed that, compared to non‐IBD controls, the incidence of ICP was increased in thiopurine exposed pregnancies (OR 7.55 [95% CI 2.52–22.57] p < 0.001) but not in non‐exposed pregnancies (OR 1.41 [95% CI 0.40–4.92], p = 0.75). Conclusions: Patients with IBD have a higher risk of ICP compared to the general population. Thiopurine exposure in patients with IBD is associated with an increased risk of ICP. Clinicians should monitor pregnant patients with IBD exposed to thiopurines for symptoms of ICP. [ABSTRACT FROM AUTHOR] |
|
Copyright of Alimentary Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
